Bradley Sheares Net Worth

The estimated Net Worth of Bradley T Sheares is at least $4.91 Million dollars as of 22 February 2023. Bradley Sheares owns over 11,243 units of Henry Schein stock worth over $2,605,630 and over the last 21 years he sold HSIC stock worth over $1,997,149. In addition, he makes $310,800 as Independent Director at Henry Schein.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Bradley Sheares HSIC stock SEC Form 4 insiders trading

Bradley has made over 16 trades of the Henry Schein stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 11,243 units of HSIC stock worth $922,713 on 22 February 2023.

The largest trade he's ever made was selling 19,564 units of Henry Schein stock on 24 June 2016 worth over $625,265. On average, Bradley trades about 681 units every 57 days since 2004. As of 22 February 2023 he still owns at least 38,861 units of Henry Schein stock.

You can see the complete history of Bradley Sheares stock trades at the bottom of the page.

Bradley Sheares biography

Dr. Bradley T. Sheares Ph.D. serves as Independent Director of the Company. He served as Chief Executive Officer of Reliant Pharmaceuticals, Inc., from January 2007 through its acquisition by GlaxoSmithKline plc in December 2007. Prior to joining Reliant, from 2001 until 2006, Dr. Sheares served as President of U.S. Human Health for Merck & Co. As a member of Merck’s management committee, Dr. Sheares had responsibility for formulating global business strategies, operations management and the development and implementation of corporate policies. He is also a director of Honeywell International (and is a member of its management development and compensation committee and retirement plan committee) and is a director and Chairman of the compensation committee of The Progressive Corporation. As the former Chief Executive Officer of Reliant Pharmaceuticals and with 20 years in the pharmaceutical industry (part of our medical and animal health businesses), Dr. Sheares brings to the Company’s Board of Directors extensive health care knowledge and experience in sales, marketing, brand management, research and development, complex regulatory and legal issues, risk management and mergers and acquisitions. As a director of other public companies, Dr. Sheares has been involved in succession planning, compensation, employee management and the evaluation of acquisition opportunities. During the past five years, Dr. Sheares served as a director of Covance Inc.

What is the salary of Bradley Sheares?

As the Independent Director of Henry Schein, the total compensation of Bradley Sheares at Henry Schein is $310,800. There are 15 executives at Henry Schein getting paid more, with Stanley Bergman having the highest compensation of $14,422,900.

How old is Bradley Sheares?

Bradley Sheares is 63, he's been the Independent Director of Henry Schein since 2010. There are 18 older and 15 younger executives at Henry Schein. The oldest executive at Henry Schein Inc. is Barry Alperin, 79, who is the Independent Director.

What's Bradley Sheares's mailing address?

Bradley's mailing address filed with the SEC is C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE, NY, 11747.

Insiders trading at Henry Schein

Over the last 21 years, insiders at Henry Schein have traded over $272,732,340 worth of Henry Schein stock and bought 23,637 units worth $1,414,559 . The most active insiders traders include Stanley M Bergman, Norman S Matthews, and Deborah Derby. On average, Henry Schein executives and independent directors trade stock every 21 days with the average trade being worth of $1,074,342. The most recent stock trade was executed by Lorelei Mc Glynn on 6 September 2024, trading 21,035 units of HSIC stock currently worth $1,457,726.

What does Henry Schein do?

henry schein, inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. the company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. a fortune 500® company and a member of the s&p 500® and nasdaq 100® indexes, henry schein employs more than 18,000 team schein members and serves more than one million customers. the company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. henry schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and henry schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. the company also offers its customers exclusive, innovative technology solutions, including practice

Complete history of Bradley Sheares stock trades at Henry Schein, Honeywell International Inc, and Progressive

Henry Schein executives and stock owners

Henry Schein executives and other stock owners filed with the SEC include:

• Stanley Bergman,
  Chairman of the Board, Chief Executive Officer
• Stanley M. Bergman,
  Exec. Chairman & CEO
• Steven Paladino,
  Chief Financial Officer, Executive Vice President, Director
• Gerald Benjamin,
  Chief Administrative Officer, Executive Vice President, Director
• James Breslawski,
  President, Vice Chairman of the Board, Director
• Mark Mlotek,
  Chief Strategic Officer, Executive Vice President, Director
• James P. Breslawski,
  Exec. Vice Chairman & Pres
• Gerald A. Benjamin,
  Exec. VP, Chief Admin. Officer & Exec. Director
• Steven Paladino,
  Exec. VP, CFO & Exec. Director
• Mark E. Mlotek,
  Exec. VP, Chief Strategic Officer & Exec. Director
• Michael Racioppi,
  Senior Vice President, Chief Merchandising Officer
• Philip Laskawy,
  Lead Independent Director
• Barry Alperin,
  Independent Director
• Joseph Herring,
  Independent Director
• Kurt Kuehn,
  Independent Director
• Bradley Sheares,
  Independent Director
• Carol Raphael,
  Independent Director
• Anne Margulies,
  Independent Director
• Elizabeth Rekow,
  Independent Director
• Shira Goodman,
  Independent Director
• Paul Brons,
  Independent Director
• James Mullins,
  Senior Vice President of Global Services
• Rene Willi,
  President, Global Dental Surgical Group
• David Brous,
  President, Strategic Business Units Group and Asia Pacific & Brazil Dental
• Steven Kess,
  President of the Santa Fe Group
• Carolynne Borders,
  Vice President - Investor Relations
• Jonathan Koch,
  Senior Vice President and Chief Executive Officer, Global Dental Group and Interim Chief Executive Officer, Henry Schein One
• Michael Ettinger,
  Senior Vice President - Corporate and Legal Affairs, Chief of Staff, Secretary
• Lorelei McGlynn,
  Chief Human Resource Officer
• Walter Siegel,
  Senior Vice President, General Counsel
• Christopher Pendergast,
  Senior Vice President, Chief Technology Officer
• Brad Connett,
  President - Henry Schein's U.S. Medical Group
• Olga Timoshkina,
  VP of Corp. Fin., Chief Accounting Officer & Corp. Controller
• Michael Saul Ettinger,
  Exec. VP & COO
• Ronald N. South,
  Sr. VP & CFO
• John Lee,
  VP of Global Compensation & Benefits
• Walter Siegel,
  Chief Legal Officer
• Graham Stanley,
  VP of Investor Relations & Strategic Fin. Project Officer
• Christopher Pendergast,
  Sr. VP & CTO
• Ronald South,
  Chief Accounting Officer & VP of Corp. Fin.
• Paul Rose,
  SVP, Global Supply Chain
• David Mc Kinley,
  President, Medical Group
• Donald J Kabat,
  Director
• Karen Prange,
  EVP&CEO Gl.AH.Med.Den.Sur.Grp
• Lawrence S Bacow,
  Director
• Robert Minowitz,
  President, Int'l Dental Group
• E Dianne Rekow,
  Director
• Peter M. Mc Carthy,
  Pres., Global Animal Health
• Bridget A Ross,
  President, Global Medical Grp
• James A. Harding,
  Chief Technology Officer
• Mohamad Ali,
  
• Deborah Derby,
  
• Michael Zack,
  Senior Vice President
• Larry Gibson,
  Executive V.P. and CTO
• Irving Shafran,
  Director
• Margaret A Hamburg,
  Director
• Marvin Schein,
  
• Pamela Joseph,
  Director
• Stanley Komaroff,
  Senior Advisor
• Lonnie Shoff,
  Pres., Global Healthcare Spec.
• Norman S Matthews,
  Director
• Louis W Sullivan,
  Director
• Karyn Mashima,
  Director
• Leonard A David,
  Vice President
• Reed Vaughn Tuckson,
  
• Scott Philip Serota,
  
• Carole T Faig,
  
• Ronald N. South,
  SVP & Chief Financial Officer